700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
|Radul Olga V, Chernomorez Dasha V and Lysenko Victoria V|
|Posters: J Cancer Sci Ther|
|Introduction:The current and important task of screening is the selection of patients for transrectal polyfokal prostate biopsy
(TRPPB) controlled transrectal ultrasound, which is based on data prostate-specific antigen (PSA), digital rectal examination
data and transrectal ultrasound (TRUS).
is a determination of specificity, accuracy, and reliability of PSA for the diagnosis of prostate cancer (PC), depending
on its absolute value.
Materials and methods:
An analysis and a study of 316 patients? diagnostic data from 2006 to 2010, which carried out by TRPPB
and controlled by TRUS within 10-14 points.
Analysis and results:
If PSA levels of 0-4 ng/ml, then the benign processes in the prostate (BPP) were found in 80% of patients,
while the PC is detected in 20% of cases. If PSA levels are 4-10 ng/ml, then BPP is in 55.7% of patients, and PC is in 44.3% of
patients. If PSA levels are 10-20 ng/ml, then BPP is in 47.2% of patients, and PC is in 52.7% of patients. If PSA level is 20 ng /
ml or more, then BPP is in 12.3% of patients, and PC is in 87.7% of patients. There is a high significant difference (p <0,001, t>
2,0) in the frequency of detection of PC in marker levels between 20 ng/ml and more. If the PSA level at 0-4 ng/ml, then the
specificity this marker is 20%; if PSA level at 4-20 ng/ml, then the specificity is at 52%; and if a PSA level at 20 ng/ml and more,
then the specificity is at 88%. There is a relationship between age men and frequency of PC. The observed satisfactory reliability
of differences (p <0,05, 0,0 |
|PDF | HTML|